LEIDEN, Netherlands, Aug. 17, 2006 (PRIMEZONE) -- Biotech company Pharming Group N.V. (“Pharming”) (Euronext:PHARM) (PHARM.AS) announced today that its Marketing Authorization Application (MAA) for recombinant human C1 inhibitor (rhC1INH or Rhucin(R)) for treatment of acute attacks of hereditary angioedema (HAE) has been accepted for review by the European Medicines Agency (EMEA). The Company further announced that it has selected Rhucin(R) as the global trade mark for rhC1INH for the treatment of acute HAE attacks.
